An interventional study of Low dose alpha-galactosidase-derived peptide and Medium dose alpha-galactosidase-derived peptide in Postprandial Glycemic Control and Prediabetic Overweight and Obese Adults, sponsored by Lembas. Recruiting at 1 site in Canada. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-12.
Sponsored by Lembas · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 189 studies in Overweight with a site in Canada — 45 open to participants now, 68 under way, 33 of them phase 3. Overweight · Canada.
Among the 189 studies in Overweight with a site in Canada, this one is the 129th largest by planned enrollment of the 160 interventional ones that give a count, is one of 38 that started in 2026, is one of 79 with no phase, reaches primary completion later than 18 of the 67 other live ones, and was the 178th registered.
3,613 studies on the registry are indexed under Overweight; 861 are open to participants now.
Browse Overweight studies →45 of the 189 studies in Overweight with a site in Canada are open now. Recruiting first, the newest first:
Pfizer · Sites in Canada, United States
Ages 18+
Alain Dagher · Sites in Canada
Ages 35–55 · Healthy volunteers
Amgen · Sites in Canada, United States
Ages 18+
McGill University Health Centre/Research Institute of the McGill University Health Centre · Sites in Canada
Ages 18–65
May Faraj, PDt, PhD · Sites in Canada
Ages 40–70 · Healthy volunteers
A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →
Of the 534 Overweight studies recruiting now, 159 (30%) set no upper age limit and 347 (65%) stop at 75 or younger; 64 take children under 18; 205 take healthy volunteers.
This study: 18 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
189 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 7 · Phase 2 24 · Phase 3 47 · Phase 4 10
First in 2001; this study’s year is marked. 38 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 35 is below the median of 78 across 3,132 interventional studies indexed under Overweight.
Median enrollment 119 across the 160 interventional studies, 1 across the 27 observational. Of the 101 that completed or were terminated, 16 (16%) have results posted.
This tab as a report to print or save as PDF → With an account.
82 of 189 have an industry lead sponsor. The 10 most frequent:
Lembas is the lead sponsor of 2 studies on the registry; 2 are open to participants now.
Lembas has 1 study filed under Overweight — fewer than ten, so there is no comparison to draw.
25 of the studies in Overweight with a site in Canada that are under way reach primary completion within a year, 10 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06962280Phase 3Eli Lilly and CompanyA Long-Term Study of Tirzepatide (LY3298176) in Adults With Type 1 Diabetes and Obesity or Overweight | 2026-11 |
| NCT06858839Phase 3AmgenEvaluation of Maridebart Cafraglutide in Adult Participants Without Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight | 2027-01-21 |
| NCT06858878Phase 3AmgenEfficacy and Safety of Maridebart Cafraglutide in Adult Participants With Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight | 2027-01-21 |
| NCT07220642Phase 3Novo Nordisk A/SWeight Loss in People Living With Overweight or Obesity Following Treatment With Cagrilintide | 2027-05-11 |
| NCT07220759Phase 3Novo Nordisk A/SWeight Loss in People Living With Overweight or Obesity and Type 2 Diabetes Following Treatment With Cagrilintide | 2027-05-12 |
Add all 25 to your calendar (.ics) → With an account.
Among the 189 studies in Overweight with a site in Canada, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of part 1 of this clinical trial is to investigate the tolerability of Lembas Edge in healthy adults. The objective of Part 2 of this study is to investigate the efficacy of Lembas Edge on postprandial glycemic control in prediabetic overweight and obese adults. The main questions it aims to answer are:
Researchers will compare Lembas Edge to placebo to see its effects. Participants will be asked to:
Inclusion Criteria Part 1:
Females not of , defined as those who have undergone a sterilization procedure (e.g. hysterectomy, bilateral oophorectomy, bilateral tubal ligation, complete endometrial ablation) or have been for at least 1 year prior to screening Or, Individuals of child-bearing potential must have a negative baseline urine pregnancy test and agree to use a medically approved method of for the duration of the study. All hormonal birth control must have been in use for a minimum of three months. Acceptable methods of birth control include:
Inclusion Criteria Part 2:
Females not of child-bearing potential, defined as those who have undergone a sterilization procedure (e.g. hysterectomy, bilateral oophorectomy, bilateral tubal ligation, complete endometrial ablation) or have been post-menopausal for at least 1 year prior to screening Or, Individuals of child-bearing potential must have a negative baseline urine pregnancy test and agree to use a medically approved method of birth control for the duration of the study. All hormonal birth control must have been in use for a minimum of three months. Acceptable methods of birth control include:
Exclusion Criteria Part 1:
Exclusion Criteria Part 2:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will be instructed to take 3 capsules of the study product in a fasted state 120 minutes before a standardized breakfast.
Dietary Supplement: Low dose alpha-galactosidase-derived peptide
Participants will be instructed to take 3 capsules of the study product in a fasted state 120 minutes before a standardized breakfast.
Dietary Supplement: Medium dose alpha-galactosidase-derived peptide
In part 1, participants will be instructed to take 3 capsules daily (as a single dose) in the morning until the day prior to their end of study visit (Day 13). In part 2, participants will be instructed to take 3 capsules of the study product in a fasted state 120 minutes before a standardized breakfast.
Dietary Supplement: High dose alpha-galactosidase-derived peptide
In part 1, participants will be instructed to take 3 capsules daily (as a single dose) in the morning until the day prior to their end of study visit (Day 13). In part 2, participants will be instructed to take 3 capsules of the study product in a fasted state 120 minutes before a standardized breakfast.
Dietary Supplement: Placebo
Participants will be instructed to take 3 capsules of the study product in a fasted state 120 minutes before a standardized breakfast.
Participants will be instructed to take 3 capsules of the study product in a fasted state 120 minutes before a standardized breakfast.
In part 1, participants will be instructed to take 3 capsules daily (as a single dose) in the morning until the day prior to their end of study visit (Day 13). In part 2, participants will be instructed to take 3 capsules of the study product in a fasted state 120 minutes before a standardized breakfast.
In part 1, participants will be instructed to take 3 capsules daily (as a single dose) in the morning until the day prior to their end of study visit (Day 13). In part 2, participants will be instructed to take 3 capsules of the study product in a fasted state 120 minutes before a standardized breakfast.
Incidence of post-emergent adverse events (AE)
Part 1. Incidence of post-emergent adverse events (AE)
Time frame: Day 0 to 14
Clinically relevant changes in blood pressure after supplementation
Part 1. Clinically relevant changes in blood pressure (mmHg) after supplementation
Time frame: Day 0 to 14
Clinically relevant changes in heart rate after supplementation
Part 1. Clinically relevant changes in heart rate (beats per minute) after supplementation
Time frame: Day 0 to 14
Clinically relevant changes in aspartate aminotransferase
Part 1. Clinically relevant changes in aspartate aminotransferase (U/L) after supplementation.
Time frame: Day 0 to 14
Clinically relevant changes in alanine aminotransferase
Part 1. Clinically relevant changes in alanine aminotransferase (U/L) after supplementation.
Time frame: Day 0 to 14
Clinically relevant changes in alkaline phosphatase
Part 1. Clinically relevant changes in alkaline phosphatase (U/L) after supplementation.
Time frame: Day 0 to 14
Clinically relevant changes in total bilirubin
Part 1. Clinically relevant changes in total bilirubin (micromole/litre) after supplementation.
Time frame: Day 0 to 14
Clinically relevant changes in creatinine
Part 1. Clinically relevant changes in creatinine (micromole/litre) after supplementation.
Time frame: Day 0 to 14
Clinically relevant changes in sodium
Part 1. Clinically relevant changes in sodium (mmol/L) after supplementation.
Time frame: Day 0 to 14
Clinically relevant changes in potassium
Part 1. Clinically relevant changes in potassium (mmol/L) after supplementation.
Time frame: Day 0 to 14
Clinically relevant changes in chloride
Part 1. Clinically relevant changes in chloride (mmol/L) after supplementation.
Time frame: Day 0 to 14
Clinically relevant changes in estimated glomerular filtration rate
Part 1. Clinically relevant changes in estimated glomerular filltration rate (mL/min/1.73 m\^2) after supplementation.
Time frame: Day 0 to 14
Clinically relevant changes in glucose
Part 1. Clinically relevant changes in glucose (mmol/L) after supplementation.
Time frame: Day 0 to 14
Clinically relevant changes in red blood cell count
Part 1. Clinically relevant changes in red blood cell count (x 10\^12/L) after supplementation
Time frame: Day 0 to 14
Clinically relevant changes in white blood cell count
Part 1. Clinically relevant changes in white blood cell count (x 10\^9/L) after supplementation
Time frame: Day 0 to 14
Clinically relevant changes in platelet count
Part 1. Clinically relevant changes in platelet count (x 10\^9/L) after supplementation
Time frame: Day 0 to 14
Clinically relevant changes in hemoglobin
Part 1. Clinically relevant changes in hemoglobin (g/L) after supplementation
Time frame: Day 0 to 14
Clinically relevant changes in hematocrit
Part 1. Clinically relevant changes in hematocrit (L/L) after supplementation
Time frame: Day 0 to 14
Clinically relevant changes in red blood cell indices (MCV - Mean Corpuscular Volume)
Part 1. Clinically relevant changes in MCV (fL) after supplementation
Time frame: Day 0 to 14
Clinically relevant changes in red blood cell indices (MCH - Mean Corpuscular Hemoglobin)
Part 1. Clinically relevant changes in MCH (pg) after supplementation
Time frame: Day 0 to 14
Clinically relevant changes in red blood cell indices (MCHC - Mean Corpuscular Hemoglobin Concentration)
Part 1. Clinically relevant changes in MCHC (g/L) after supplementation
Time frame: Day 0 to 14
Clinically relevant changes in RDW - Red Cell Distribution Width
Part 1. Clinically relevant changes in RDW (%) after supplementation
Time frame: Day 0 to 14
Clinically relevant changes in red blood cell indices (MPV - Mean Platelet Volume)
Part 1. Clinically relevant changes in MPV (fL) after supplementation
Time frame: Day 0 to 14
The difference in postprandial glucose between Lembas Edge and placebo
Part 2. The difference in postprandial glucose, as assessed by incremental area under the curve (iAUC) (0-120 min), between Lembas Edge (high dose, medium dose, low dose) and placebo.
Time frame: Visit 2 (day 1) to Visit 5 (day 22)
The height of the postprandial glucose peak and nadir post meal between Lembas Edge and placebo
Part 2. The height of the postprandial glucose peak and nadir post meal between Lembas Edge (high dose, medium dose, low dose) and placebo.
Time frame: Visit 2 (day 1) to Visit 5 (day 22)
The difference in postprandial glucose iAUC (0-240 min) between Lembas Edge and placebo
Part 2. The difference in postprandial glucose, as assessed by iAUC (0-240 min), between Lembas Edge (high dose, medium dose, low dose) and placebo
Time frame: Visit 2 (day 1) to Visit 5 (day 22)
The difference in postprandial insulin between Lembas Edge and placebo
Part 2. The difference in postprandial insulin, as assessed by iAUC (0-120 min) and iAUC (0-240 min), between Lembas Edge (high dose, medium dose, low dose) and placebo
Time frame: Visit 2 (day 1) to Visit 5 (day 22)
The difference in self-reported satiety scores between Lembas Edge and placebo
Part 2. The difference in self-reported satiety scores, as assessed by iAUC (0-240 min), between Lembas Edge (high dose, medium dose, low dose) and placebo
Time frame: Visit 2 (day 1) to Visit 5 (day 22)
The difference in total calories consumed from the standardized meal between Lembas Edge an placebo
Part 2. The difference in total calories consumed from the standardized meal provided on an ad libitum basis at time = 240 minutes between Lembas Edge (high dose, medium dose, low dose) and placebo
Time frame: Visit 2 (day 1) to Visit 5 (day 22), time = 240 minutes
Change in fasting glucose from baseline to day 14 after supplementation
Part 1. The change in fasting glucose from baseline to day 14 after supplementation
Time frame: Day 0 to 14
Change in fasting insulin from baseline to day 14 after supplementation
Part 1. The change in fasting insulin from baseline to day 14 after supplementation
Time frame: Day 0 to 14
Change in fasting HOMA-IR from baseline to day 14 after supplementation
Part 1. The change in Homeostasis Model Assessment of Insulin Resistance (HOMA-IR) from baseline to day 14 after supplementation
Time frame: Day 0 to 14
Part 2. Incidence of post-emergent adverse events (AE)
Part 2. Incidence of post-emergent adverse events (AE)
Time frame: Visit 1 (day -45 to -1) to visit 5 (day 22)
The difference in postprandial peptide YY (PYY) between Lembas Edge and placebo
Part 2. The difference in postprandial PYY, as assessed by iAUC (0-240 min), between Lembas Edge (high dose, medium dose, low dose) and placebo
Time frame: Day 1 to 22
The difference in postprandial GIP (Glucose-Dependent Insulinotropic Polypeptide) between Lembas Edge and placebo
Part 2. The difference in postprandial GIP, as assessed by iAUC (0-240 min), between Lembas Edge (high dose, medium dose, low dose) and placebo
Time frame: Day 1 to 22
The difference in postprandial Glucagon-Like Peptide-1 (GLP-1) between Lembas Edge and placebo
Part 2. The difference in postprandial GLP-1, as assessed by iAUC (0-240 min), between Lembas Edge (high dose, medium dose, low dose) and placebo
Time frame: Day 1 to 22
Started Oct 2026 (actual). Primary completion is estimated for Feb 2027, 4 months after the start.
Of 112 industry-sponsored interventional studies with no phase under Overweight, half reached primary completion within 11 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 25. This study's planned 4 months is below that.
Counting every sponsor, half of 1,420 studies reached it within 17 months; a quarter within 8 and three quarters within 38.
Start moved once since we started tracking on Sep 25, 2026: Sep 2026 → Oct 2026, on Sep 25, 2026.
Primary completion moved once since we started tracking on Sep 25, 2026: Jan 2027 → Feb 2027, on Nov 12, 2026.
Completion moved once since we started tracking on Sep 25, 2026: Jan 2027 → Feb 2027, on Nov 12, 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.